Cargando…
Thalidomide as a potential adjuvant treatment for paraneoplastic pemphigus: A single‐center experience
Paraneoplastic pemphigus (PNP) is a rare autoimmune bullous disease associated with an underlying malignancy. The survival rate at 5 years is reported to be as low as 38%. Thalidomide is a medication with strong anti‐inflammatory, immunomodulatory, antiangiogenic, and sedative properties. Recently,...
Autores principales: | Wang, Jingying, Zhang, Yan, Pan, Meng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816226/ https://www.ncbi.nlm.nih.gov/pubmed/32990359 http://dx.doi.org/10.1111/dth.14353 |
Ejemplares similares
-
Successful treatment with thalidomide for pemphigus vulgaris
por: Zhang, Bingjie, et al.
Publicado: (2020) -
Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
por: FAN, Birao, et al.
Publicado: (2022) -
Castleman's Disease with Paraneoplastic Pemphigus
por: Dinesha,, et al.
Publicado: (2014) -
Paraneoplastic Pemphigus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa
por: Kim, Jong Hoon, et al.
Publicado: (2019) -
Paraneoplastic pemphigus: a short review
por: Wieczorek, Marta, et al.
Publicado: (2016)